The University of Chicago Header Logo

Michael Thirman

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
Email
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA215504     (THIRMAN, MICHAEL J)Mar 1, 2017 - Feb 28, 2022
    NIH
    Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
    Role: Principal Investigator
    R01CA104449     (THIRMAN, MICHAEL J)Jul 1, 2004 - Apr 30, 2010
    NIH
    MLL Fusions and cooperating mutations in acute leukemia
    Role: Principal Investigator
    R01CA078431     (THIRMAN, MICHAEL J)Apr 1, 1999 - Jan 31, 2005
    NIH
    GENETIC ANALYSIS OF THE MLL-ELL FUSION PROTEIN
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, Zucenka A, De Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, Kühn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, Döhner H, Greco C, Kovacsovics TJ, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly JS. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025 May 07. PMID: 40332046.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2. Pullarkat V, Pratz KW, Döhner H, Recher C, Thirman MJ, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang JH, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M. Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood Cancer J. 2025 Mar 28; 15(1):49. PMID: 40155601; PMCID: PMC11953227.
      Citations:    Fields:    
    3. Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222. PMID: 39133921; PMCID: PMC11600046.
      Citations: 33     Fields:    Translation:Humans
    4. Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 Jan; 43(1):75-84. PMID: 39121437; PMCID: PMC11687943.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    5. Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Patel AA. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867. PMID: 38441062.
      Citations: 1     Fields:    Translation:Humans
    6. Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 04; 99(4):615-624. PMID: 38343151.
      Citations: 72     Fields:    Translation:Humans
    7. Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, Wanjari P, Segal J, Venkataraman G, Cheng JX, Gurbuxani S, Lager A, Fitzpatrick C, Thirman M, Nawas M, Liu H, Drazer M, Odenike O, Larson R, Stock W, Saygin C. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171. PMID: 38039510; PMCID: PMC10787242.
      Citations: 6     Fields:    Translation:Humans
    8. Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239. PMID: 36655425; PMCID: PMC10388285.
      Citations:    Fields:    Translation:Humans
    9. Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023 03; 615(7954):920-924. PMID: 36922593; PMCID: PMC10060155.
      Citations: 185     Fields:    Translation:HumansCellsCTClinical Trials
    10. Tirtakusuma R, Szoltysek K, Milne P, Grinev VV, Ptasinska A, Chin PS, Meyer C, Nakjang S, Hehir-Kwa JY, Williamson D, Cauchy P, Keane P, Assi SA, Ashtiani M, Kellaway SG, Imperato MR, Vogiatzi F, Schweighart EK, Lin S, Wunderlich M, Stutterheim J, Komkov A, Zerkalenkova E, Evans P, McNeill H, Elder A, Martinez-Soria N, Fordham SE, Shi Y, Russell LJ, Pal D, Smith A, Kingsbury Z, Becq J, Haas OA, Carey P, Bailey S, Skinner R, Miakova N, Collin M, Bigley V, Haniffa M, Marschalek R, Harrison CJ, Cargo CA, Schewe D, Olshanskaya Y, Thirman MJ, Cockerill PN, Mulloy JC, Blair HJ, Vormoor J, Allan JM, Bonifer C, Heidenreich O, Bomken S, Eckert C. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. Blood. 2022 10 27; 140(17):1875-1890. PMID: 35839448; PMCID: PMC10488321.
      Citations: 29     Fields:    Translation:HumansCells
    11. Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, Kantarjian HM, DiNardo CD, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Wei AH. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clin Cancer Res. 2022 07 01; 28(13):2744-2752. PMID: 35063965; PMCID: PMC9365380.
      Citations: 46     Fields:    Translation:Humans
    12. Pratz KW, Jonas BA, Pullarkat V, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Recher C, Döhner H. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2022 03 10; 40(8):855-865. PMID: 34910556; PMCID: PMC8906463.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    13. Patel AA, Heng J, Dworkin E, Monick S, Derman BA, DuVall AS, Gurbuxani S, Kosuri S, Liu H, Thirman M, Godley LA, Odenike O, Larson RA, Stock W. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420. PMID: 35844676; PMCID: PMC9175801.
      Citations: 5     
    14. Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS, Chyla B, Hong WJ, Jiang Q, Potluri J, DiNardo CD. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021 02 01; 96(2):208-217. PMID: 33119898.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    15. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Porkka K, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW, Döhner H, Hájek R, Illés Á. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 08 13; 383(7):617-629. PMID: 32786187.
      Citations: 1243     Fields:    Translation:HumansCTClinical Trials
    16. Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, Kosuri S, Artz AS, Larson RA, Stock W, Segal J, Odenike O. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51. PMID: 32358888.
      Citations: 18     Fields:    Translation:Humans
    17. Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606. PMID: 32074275; PMCID: PMC7042987.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    18. Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, Moliterno A, Ji P, Levine RL, Godley LA, Steidl U, Bieker JJ, List AF, Saunthararajah Y, He C, Verma A, Wickrema A. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discov. 2019 06; 9(6):778-795. PMID: 30944118; PMCID: PMC6697164.
      Citations: 37     Fields:    Translation:HumansCells
    19. Awan FT, Thirman MJ, Patel-Donnelly D, Assouline S, Rao AV, Ye W, Hill B, Sharman JP. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Leuk Lymphoma. 2019 08; 60(8):1972-1977. PMID: 30633573.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    20. Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RA. Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657. PMID: 30423270.
      Citations: 29     Fields:    Translation:Humans
    21. Byrd JC, Ruppert AS, Heerema NA, Halvorson AE, Hoke E, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman MJ, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar SJ, Larson RA. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv. 2018 07 24; 2(14):1705-1718. PMID: 30030269; PMCID: PMC6058242.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    22. Baron BW, Thirman MJ, Giurcanu MC, Baron JM. Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. Acta Haematol. 2018; 139(2):132-139. PMID: 29444501.
      Citations: 13     Fields:    Translation:Humans
    23. DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 02; 19(2):216-228. PMID: 29339097.
      Citations: 377     Fields:    Translation:HumansCTClinical Trials
    24. Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek JE, Curran E, Pettit K, Stock W, Liu H. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4. PMID: 29304833; PMCID: PMC5756334.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    25. Lin S, Luo RT, Shrestha M, Thirman MJ, Mulloy JC. The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment. Blood. 2017 08 17; 130(7):903-907. PMID: 28637661; PMCID: PMC5561902.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    26. Thirman MJ. Paradoxical Effects of MLL Paralogs in MLL-Rearranged Leukemia. Cancer Cell. 2017 06 12; 31(6):729-731. PMID: 28609652; PMCID: PMC5783294.
      Citations: 2     Fields:    Translation:Humans
    27. Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner H, Thirman M, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YL. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017 May 09; 1(12):715-727. PMID: 29296715; PMCID: PMC5728051.
      Citations: 72     Fields:    
    28. Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock W. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7. PMID: 28278716.
      Citations: 12     Fields:    Translation:Humans
    29. Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, Imamura T, Kaberlein JJ, Rayes A, Althoff MJ, Anastasi J, O'Brien MM, Meetei AR, Milne TA, Bonifer C, Mulloy JC, Thirman MJ. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):737-749. PMID: 27846391.
      Citations: 71     Fields:    Translation:HumansAnimals
    30. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S, Österborg A. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct; 17(10):1409-1418. PMID: 27637985.
      Citations: 161     Fields:    Translation:HumansCellsCTClinical Trials
    31. Wang QF, Li YJ, Dong JF, Li B, Kaberlein JJ, Zhang L, Arimura FE, Luo RT, Ni J, He F, Wu J, Mattison R, Zhou J, Wang CZ, Prabhakar S, Nobrega MA, Thirman MJ. Regulation of MEIS1 by distal enhancer elements in acute leukemia. Leukemia. 2014 Jan; 28(1):138-46. PMID: 24022755; PMCID: PMC5774621.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    32. Baron BW, Anastasi J, Bies J, Reddy PL, Joseph L, Thirman MJ, Wroblewski K, Wolff L, Baron JM. GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas. Blood Cells Mol Dis. 2014 Jan; 52(1):68-75. PMID: 23910958; PMCID: PMC4272826.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    33. Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43. PMID: 23771005; PMCID: PMC4279870.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    34. Grdina DJ, Murley JS, Miller RC, Mauceri HJ, Sutton HG, Thirman MJ, Li JJ, Woloschak GE, Weichselbaum RR. A manganese superoxide dismutase (SOD2)-mediated adaptive response. Radiat Res. 2013 Feb; 179(2):115-24. PMID: 23237540; PMCID: PMC3594688.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    35. Baron BW, Anastasi J, Hyjek EM, Bies J, Reddy PL, Dong J, Joseph L, Thirman MJ, Wroblewski K, Wolff L, Baron JM. PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas. Proc Natl Acad Sci U S A. 2012 Apr 10; 109(15):5735-9. PMID: 22451912; PMCID: PMC3326467.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    36. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50. PMID: 21913806.
      Citations: 7     Fields:    Translation:Humans
    37. Artz AS, Thirman MJ. Unexplained anemia predominates despite an intensive evaluation in a racially diverse cohort of older adults from a referral anemia clinic. J Gerontol A Biol Sci Med Sci. 2011 Aug; 66(8):925-32. PMID: 21659341.
      Citations: 45     Fields:    Translation:Humans
    38. Wang QF, Wu G, Mi S, He F, Wu J, Dong J, Luo RT, Mattison R, Kaberlein JJ, Prabhakar S, Ji H, Thirman MJ. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood. 2011 Jun 23; 117(25):6895-905. PMID: 21518926; PMCID: PMC3128481.
      Citations: 82     Fields:    Translation:HumansAnimalsCells
    39. Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock W. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214. PMID: 21421110.
      Citations: 12     Fields:    Translation:Humans
    40. Baron BW, Hyjek E, Gladstone B, Thirman MJ, Baron JM. PDCD2, a protein whose expression is repressed by BCL6, induces apoptosis in human cells by activation of the caspase cascade. Blood Cells Mol Dis. 2010 Aug 15; 45(2):169-75. PMID: 20605493.
      Citations: 21     Fields:    Translation:HumansCells
    41. Mi S, Li Z, Chen P, He C, Cao D, Elkahloun A, Lu J, Pelloso LA, Wunderlich M, Huang H, Luo RT, Sun M, He M, Neilly MB, Zeleznik-Le NJ, Thirman MJ, Mulloy JC, Liu PP, Rowley JD, Chen J. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A. 2010 Feb 23; 107(8):3710-5. PMID: 20133587; PMCID: PMC2840429.
      Citations: 84     Fields:    Translation:HumansAnimalsCells
    42. Byun JS, Wong MM, Cui W, Idelman G, Li Q, De Siervi A, Bilke S, Haggerty CM, Player A, Wang YH, Thirman MJ, Kaberlein JJ, Petrovas C, Koup RA, Longo D, Ozato K, Gardner K. Dynamic bookmarking of primary response genes by p300 and RNA polymerase II complexes. Proc Natl Acad Sci U S A. 2009 Nov 17; 106(46):19286-91. PMID: 19880750; PMCID: PMC2780808.
      Citations: 38     Fields:    Translation:HumansCells
    43. Li Z, Luo RT, Mi S, Sun M, Chen P, Bao J, Neilly MB, Jayathilaka N, Johnson DS, Wang L, Lavau C, Zhang Y, Tseng C, Zhang X, Wang J, Yu J, Yang H, Wang SM, Rowley JD, Chen J, Thirman MJ. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res. 2009 Feb 01; 69(3):1109-16. PMID: 19155294; PMCID: PMC2633429.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    44. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, Neilly MB, Jin J, Zhang Y, Bohlander SK, Zhang DE, Larson RA, Le Beau MM, Thirman MJ, Golub TR, Rowley JD, Chen J. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008 Oct 07; 105(40):15535-40. PMID: 18832181; PMCID: PMC2563085.
      Citations: 227     Fields:    Translation:HumansAnimals
    45. Chen J, Santillan DA, Koonce M, Wei W, Luo R, Thirman MJ, Zeleznik-Le NJ, Diaz MO. Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. Cancer Res. 2008 Aug 01; 68(15):6199-207. PMID: 18676843; PMCID: PMC2734520.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    46. Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7. PMID: 18297531.
      Citations: 2     Fields:    Translation:Humans
    47. Baron BW, Zeleznik-Le N, Baron MJ, Theisler C, Huo D, Krasowski MD, Thirman MJ, Baron RM, Baron JM. Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas. Proc Natl Acad Sci U S A. 2007 May 01; 104(18):7449-54. PMID: 17468402; PMCID: PMC1863460.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    48. Hahn J, Xiao W, Jiang F, Simone F, Thirman MJ, Wang Z. Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL-binding domain. Prostate. 2007 Feb 01; 67(2):146-53. PMID: 17044034; PMCID: PMC2801832.
      Citations: 13     Fields:    Translation:HumansCells
    49. Markus J, Garin MT, Bies J, Galili N, Raza A, Thirman MJ, Le Beau MM, Rowley JD, Liu PP, Wolff L. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16). Cancer Res. 2007 Feb 01; 67(3):992-1000. PMID: 17283131.
      Citations: 10     Fields:    Translation:HumansCells
    50. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64. PMID: 16920562.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    51. Alexander JJ, Aneziokoro OG, Chang A, Hack BK, Markaryan A, Jacob A, Luo R, Thirman M, Haas M, Quigg RJ. Distinct and separable roles of the complement system in factor H-deficient bone marrow chimeric mice with immune complex disease. J Am Soc Nephrol. 2006 May; 17(5):1354-61. PMID: 16597679.
      Citations: 14     Fields:    Translation:AnimalsCells
    52. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38. PMID: 16009946.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    53. Simone F, Viengchareun S, Meduri G, Thirman MJ, Pascual-Le Tallec L, Lombès M. The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions. Mol Endocrinol. 2005 May; 19(5):1158-69. PMID: 15650021.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    54. Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JM. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14198-203. PMID: 15375218; PMCID: PMC521136.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    55. Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Odenike T, Stock W. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4. PMID: 15155474.
      Citations: 2     Fields:    Translation:HumansCells
    56. Polak PE, Simone F, Kaberlein JJ, Luo RT, Thirman MJ. ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia. Mol Biol Cell. 2003 Apr; 14(4):1517-28. PMID: 12686606; PMCID: PMC153119.
      Citations: 19     Fields:    Translation:HumansCells
    57. Simone F, Luo RT, Polak PE, Kaberlein JJ, Thirman MJ. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. Blood. 2003 Mar 15; 101(6):2355-62. PMID: 12446457.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    58. Baron BW, Anastasi J, Thirman MJ, Furukawa Y, Fears S, Kim DC, Simone F, Birkenbach M, Montag A, Sadhu A, Zeleznik-Le N, McKeithan TW. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. Proc Natl Acad Sci U S A. 2002 Mar 05; 99(5):2860-5. PMID: 11854457; PMCID: PMC122438.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    59. Luo RT, Lavau C, Du C, Simone F, Polak PE, Kawamata S, Thirman MJ. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. Mol Cell Biol. 2001 Aug; 21(16):5678-87. PMID: 11463848; PMCID: PMC87288.
      Citations: 37     Fields:    Translation:AnimalsCells
    60. Simone F, Polak PE, Kaberlein JJ, Luo RT, Levitan DA, Thirman MJ. EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. Blood. 2001 Jul 01; 98(1):201-9. PMID: 11418481.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    61. Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci U S A. 2000 Sep 26; 97(20):10984-9. PMID: 10995463; PMCID: PMC27135.
      Citations: 53     Fields:    Translation:AnimalsCells
    62. Lavau C, Du C, Thirman M, Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J. 2000 Sep 01; 19(17):4655-64. PMID: 10970858; PMCID: PMC302066.
      Citations: 66     Fields:    Translation:AnimalsCells
    63. Thirman MJ, Diskin EB, Bin SS, Ip HS, Miller JM, Simon MC. Developmental analysis and subcellular localization of the murine homologue of ELL. Proc Natl Acad Sci U S A. 1997 Feb 18; 94(4):1408-13. PMID: 9037066; PMCID: PMC19804.
      Citations: 6     Fields:    Translation:AnimalsCells
    64. Tanabe S, Zeleznik-Le NJ, Kobayashi H, Vignon C, Espinosa R, LeBeau MM, Thirman MJ, Rowley JD. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line. Genes Chromosomes Cancer. 1996 Apr; 15(4):206-16. PMID: 8703846.
      Citations: 7     Fields:    Translation:HumansCells
    65. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996 Apr; 10(2):293-320. PMID: 8707757.
      Citations: 25     Fields:    Translation:Humans
    66. Broeker PL, Super HG, Thirman MJ, Pomykala H, Yonebayashi Y, Tanabe S, Zeleznik-Le N, Rowley JD. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood. 1996 Mar 01; 87(5):1912-22. PMID: 8634439.
      Citations: 69     Fields:    Translation:HumansCells
    67. Martinez-Climent JA, Espinosa R, Thirman MJ, Le Beau MM, Rowley JD. Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias. Identification of the t(9;11) as an indicator of long survival. J Pediatr Hematol Oncol. 1995 Nov; 17(4):277-83. PMID: 7583381.
      Citations: 7     Fields:    Translation:HumansCells
    68. Martinez-Climent JA, Thirman MJ, Espinosa R, Le Beau MM, Rowley JD. Detection of 11q23/MLL rearrangements in infant leukemias with fluorescence in situ hybridization and molecular analysis. Leukemia. 1995 Aug; 9(8):1299-304. PMID: 7643616.
      Citations: 7     Fields:    Translation:HumansCells
    69. Kobayashi H, Thirman MJ, Rowley JD. U937 cell line has a t(10;11)(p13-14;q14-21) rather than a deletion of 11q. Genes Chromosomes Cancer. 1995 Jul; 13(3):217-8. PMID: 7669742.
      Citations: 3     Fields:    Translation:HumansCells
    70. Mbangkollo D, Burnett R, McCabe N, Thirman M, Gill H, Yu H, Rowley JD, Diaz MO. The human MLL gene: nucleotide sequence, homology to the Drosophila trx zinc-finger domain, and alternative splicing. DNA Cell Biol. 1995 Jun; 14(6):475-83. PMID: 7598802.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    71. Thirman MJ, Levitan DA, Kobayashi H, Simon MC, Rowley JD. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc Natl Acad Sci U S A. 1994 Dec 06; 91(25):12110-4. PMID: 7991593; PMCID: PMC45386.
      Citations: 73     Fields:    Translation:HumansCells
    72. Stock W, Thirman MJ, Dodge RK, Rowley JD, Diaz MO, Wurster-Hill D, Sobol RE, Davey FR, Larson RA, Westbrook CA, et al. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. Leukemia. 1994 Nov; 8(11):1918-22. PMID: 7967737.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    73. Burnett RC, Thirman MJ, Rowley JD, Diaz MO. Molecular analysis of the T-cell acute lymphoblastic leukemia-associated t(1;7)(p34;q34) that fuses LCK and TCRB. Blood. 1994 Aug 15; 84(4):1232-6. PMID: 8049439.
      Citations: 7     Fields:    Translation:HumansCells
    74. Thirman MJ, Albrecht JH, Krueger MA, Erickson RR, Cherwitz DL, Park SS, Gelboin HV, Holtzman JL. Induction of cytochrome CYPIA1 and formation of toxic metabolites of benzo[a]pyrene by rat aorta: a possible role in atherogenesis. Proc Natl Acad Sci U S A. 1994 Jun 07; 91(12):5397-401. PMID: 8202497; PMCID: PMC44002.
      Citations: 13     Fields:    Translation:AnimalsCells
    75. McCabe NR, Kipiniak M, Kobayashi H, Thirman M, Gill H, Rowley JD, Diaz MO. DNA rearrangements and altered transcripts of the MLL gene in a human T-ALL cell line Karpas 45 with a t(X;11) (q13;q23) translocation. Genes Chromosomes Cancer. 1994 Mar; 9(3):221-4. PMID: 7515665.
      Citations: 3     Fields:    Translation:HumansCells
    76. Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, Philip P, Diaz MO, Rowley JD. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993 Dec 15; 82(12):3705-11. PMID: 8260707.
      Citations: 88     Fields:    Translation:HumansCells
    77. Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-van der Poel S, Kaneko Y, Morgan R, Sandberg AA, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med. 1993 Sep 23; 329(13):909-14. PMID: 8361504.
      Citations: 106     Fields:    Translation:HumansCells
    78. Kobayashi H, Espinosa R, Thirman MJ, Fernald AA, Shannon K, Diaz MO, Le Beau MM, Rowley JD. Do terminal deletions of 11q23 exist? Identification of undetected translocations with fluorescence in situ hybridization. Genes Chromosomes Cancer. 1993 Aug; 7(4):204-8. PMID: 7692945.
      Citations: 4     Fields:    Translation:HumansCells
    79. Kobayashi H, Espinosa R, Thirman MJ, Gill HJ, Fernald AA, Diaz MO, Le Beau MM, Rowley JD. Heterogeneity of breakpoints of 11q23 rearrangements in hematologic malignancies identified with fluorescence in situ hybridization. Blood. 1993 Jul 15; 82(2):547-51. PMID: 8329710.
      Citations: 6     Fields:    Translation:HumansCells
    80. Kobayashi H, Espinosa R, Thirman MJ, Davis EM, Diaz MO, Le Beau MM, Rowley JD. Variability of 11q23 rearrangements in hematopoietic cell lines identified with fluorescence in situ hybridization. Blood. 1993 Jun 01; 81(11):3027-33. PMID: 8499638.
      Citations: 2     Fields:    Translation:HumansCells
    81. Jani Sait SN, Raimondi SC, Look AT, Gill H, Thirman M, Diaz MO, Shows TB. A t(11;12) 11q23 leukemic breakpoint that disrupts the MLL gene. Genes Chromosomes Cancer. 1993 May; 7(1):28-31. PMID: 7688552.
      Citations:    Fields:    Translation:HumansCells
    82. McCabe NR, Burnett RC, Gill HJ, Thirman MJ, Mbangkollo D, Kipiniak M, van Melle E, Ziemin-van der Poel S, Rowley JD, Diaz MO. Cloning of cDNAs of the MLL gene that detect DNA rearrangements and altered RNA transcripts in human leukemic cells with 11q23 translocations. Proc Natl Acad Sci U S A. 1992 Dec 15; 89(24):11794-8. PMID: 1465401; PMCID: PMC50643.
      Citations: 19     Fields:    Translation:HumansCells
    83. Thirman MJ, Devine SM, O'Toole K, Cizek G, Jessurun J, Hertz M, Geller RB. Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992 Sep; 10(3):307-11. PMID: 1422484.
      Citations: 10     Fields:    Translation:Humans
    84. Goetting MG, Thirman MJ. Neurotoxicity of meperidine. Ann Emerg Med. 1985 Oct; 14(10):1007-9. PMID: 4037466.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    Thirman's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (411)
    Explore
    _
    Co-Authors (40)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _